Goldman Remains Cautious on Myriad (MYGN) Following Q2 Results; Moves PT to $22
Tweet Send to a Friend
Goldman Sachs bumps its price target on Myriad Genetics (Nasdaq: MYGN) from $20 to $22, while remaining Neutral following FQ214 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
